(68)Ga DOTATATE uptake in vertebral hemangioma
Claudia Brogsitter1, Thomas Hofmockel, Jörg Kotzerke
1From the Departments of *Nuclear Medicine, and †Radiology, Carl Gustav Carus Medical School, University of Dresden, Dresden, Germany.
Clinical Nuclear Medicine
|October 25, 2013
Summary
Gallium-68 DOTATATE scintigraphy can identify neuroendocrine tumors but may also show uptake in vertebral hemangiomas. This case highlights vertebral hemangiomas as a benign differential diagnosis in somatostatin receptor imaging.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Somatostatin receptor scintigraphy is a key imaging technique for well-differentiated neuroendocrine tumors.
- Somatostatin receptor analogs can accumulate in inflammatory conditions like tuberculosis.
- Normal distribution patterns of Gallium-68 DOTATATE (Ga DOTATATE) are documented.
Observation:
- A 69-year-old patient with a rectal neuroendocrine tumor exhibited Ga DOTATATE uptake in two vertebral bodies.
- Computed tomography (CT) scans clearly identified these vertebral lesions as hemangiomas.
- This specific pattern of Ga DOTATATE uptake in vertebral hemangiomas has not been previously reported.
Findings:
- Ga DOTATATE uptake occurred in vertebral hemangiomas, mimicking potential metastatic disease.
- CT imaging was crucial in differentiating hemangiomas from neoplastic lesions.
- The study identifies vertebral hemangiomas as a potential benign finding on somatostatin receptor imaging.
Implications:
- Clinicians should consider vertebral hemangiomas in the differential diagnosis for unexpected Ga DOTATATE uptake.
- Accurate interpretation of somatostatin receptor imaging requires awareness of benign mimics.
- This finding can help prevent misdiagnosis and unnecessary interventions in patients undergoing neuroendocrine tumor evaluation.
